

31 October 2006

The Manager Companies  
Australian Stock Exchange Limited  
20 Bridge Street  
SYDNEY NSW 2000

(1 page by email)

Dear Madam,

**ANTI-HCV COMPOUND PRESENTATION TO INTERNATIONAL MEETING, BOSTON USA**

The Directors are pleased to advise that Biotron Limited ('Biotron') has presented preclinical efficacy data on its anti-Hepatitis C Virus (HCV) program at the 1st International Meeting on HCV: Resistance and Novel Compounds, in Boston USA.

Biotron's selection to participate in this prestigious invitation-only conference underlines the competitiveness of its anti-HCV approach, and demonstrates international interest in this antiviral program.

Biotron presented preclinical data showing the antiviral effect of selected Biotron compounds in primary hepatocyte cultures infected with either GBV-B or BVDV. Because HCV is unable to grow in cell cultures, these animal viruses, which are closely related to HCV, are used by the scientific community and pharmaceutical industry to identify compounds for progression into HCV clinical development programs.

Biotron compounds were found to inhibit production of the HCV virus surrogates from infected cells.

Biotron compounds represent a new class of inhibitors that have the potential to disrupt the establishment and continued propagation of HCV infection. The data suggests that the compounds have the potential to significantly impact on HCV viral pathogenesis when used alone or in combination with existing antiviral strategies.

As previously advised, Biotron's lead drug BIT225, currently in development by the Company for treatment of HIV-1, has good anti-HCV activity in these surrogate virus infection models. Utilising the preclinical development work already completed for the Phase I/IIa anti-HIV human trial which is due to commence in early 2007, BIT225 may be 'fast-tracked' into a human trial against HCV.

For further information, please contact Dr Michelle Miller, CEO, on (61-2) 61258001.

Yours faithfully



Peter J. Nightingale  
Company Secretary

pjn3673